SAN FRANCISCO—Paula Green, Senior Vice President of Human Resources at Twist Bioscience Corp (NASDAQ:TWST), recently sold a portion of her holdings in the company. The stock, which according to InvestingPro data has gained over 12% in the past week and maintains a "GOOD" overall financial health score, has shown significant momentum lately. According to a recent SEC filing, Green sold 282 shares of Twist Bioscience's common stock on December 20, 2024, at a price of $44.903 per share, amounting to a total transaction value of $12,662.
Following this transaction, Green retains ownership of 133,433 shares in the company. The sale was conducted to cover tax withholding obligations related to the vesting of Restricted Stock Units, as mandated by the company's equity incentive plans.
In other recent news, Twist Bioscience has reported noteworthy developments. The company's fiscal year 2024 concluded with a 27% increase in Q4 revenues to $84.7 million, and a total annual revenue growth of 28% reaching $330 million. Twist Bioscience also exceeded its gross margin guidance for the quarter, achieving 45.1%, and saw an annual gross margin improvement to 42.6%.
Baird has reaffirmed its Outperform rating on Twist Bioscience, raising its price target to $48.00. Similarly, TD Cowen maintained its Buy rating on the company, highlighting the company's solid financial guidance for fiscal year 2025. Scotiabank (TSX:BNS) also raised its price target for the company to $54, maintaining a Sector Outperform rating.
These recent developments indicate a positive outlook for Twist Bioscience. The company's initial guidance for FY25 anticipates revenue growth between 17% to 20% year-over-year, largely driven by the Next (LON:NXT) Generation Sequencing (NGS) and Synthetic Biology (SynBio) sectors. Furthermore, Twist Bioscience is expected to improve its adjusted EBITDA by roughly $30 million year-over-year. The company's strong financial position was further bolstered by a $15 million upfront payment received from Xoma (NASDAQ:XOMA) as part of a royalty purchase agreement.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.